(Q34269289)

1 August 2017

Two years' experience with denosumab for children with osteogenesis imperfecta type VI (English)

1 reference

1 August 2017

osteogenesis imperfecta

0 references

Oliver Semler

5

0 references

author name string

Heike Hoyer-Kuhn

1

1 reference

1 August 2017

Christian Netzer

2

1 reference

1 August 2017

Friederike Koerber

3

1 reference

1 August 2017

Eckhard Schoenau

4

1 reference

1 August 2017

26 September 2014

1 reference

Orphanet Journal of Rare Diseases

1 August 2017

1 reference

1 August 2017

9

1 reference

1 August 2017

145

1 reference

Creative Commons Attribution 4.0 International

1 August 2017

start time

26 September 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13023-014-0145-1

0 references

cites work

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Denosumab treatment for fibrous dysplasia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Mutations in SERPINF1 cause osteogenesis imperfecta type VI

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Denosumab in postmenopausal women with low bone mineral density

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

6 July 2018

Osteogenesis imperfecta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Collagen markers deoxypyridinoline and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

The gross motor function measure: a means to evaluate the effects of physical therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.

6 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Brief assessment of motor function: reliability and concurrent validity of the Gross Motor Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Introduction of a new standardized assessment score of spine morphology in osteogenesis imperfecta.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4180531

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

28 October 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-014-0145-1

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment

21 January 2018

1 reference

12 December 2020

PEDF regulates osteoclasts via osteoprotegerin and RANKL

1 reference

12 December 2020

Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta

1 reference

12 December 2020

Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI

1 reference

12 December 2020

First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI

1 reference

12 December 2020

Denosumab for post-transplantation hypercalcemia in osteopetrosis

1 reference

12 December 2020

10.1186/S13023-014-0145-1

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference

1 August 2017

1 reference